| E6AP promotes the degradation of the PML tumor suppressor. | None |
| Results provide insight into a dynamic pool of cytoplasmic nucleoporins that form a complex with the tumor suppressor protein PML during the G1 phase of the cell cycle. | None |
| results together with earlier work are consistent with the idea that SUMOylation regulates targeting of E1B-55K to PML-containing subnuclear structures, known to control transcriptional regulation, tumour suppression, DNA repair and apoptosis | None |
| Upregulation of the PML tumor suppressor in cellular senescence triggered by diverse drugs including clinically used anti-cancer chemotherapeutics relies on stimulation of PML transcription by JAK/STAT-mediated signaling. | None |
| PML functions in apoptosis regulation and tumor suppression are mediated by direct interaction with Fas. | None |
| The function, regulation and therapeutic implications of the tumor suppressor protein, PML | None |
| Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment | None |
| Novel function of the tumor suppressor PML at ER-mitochondria sites in the control of autophagy | None |
| Alteration of the PML proto-oncogene in leukemic cells does not abrogate expression of MHC class I antigens. | leukemia, |
| Potentiation of GATA-2 activity through interactions with the promyelocytic leukemia protein (PML) and the t(15;17)-generated PML-retinoic acid receptor alpha oncoprotein. | leukemia, |
| Proto-oncogene PML enhances antigen presentation by MHC class I molecules in human lung cancer cells. | lung, |
| Promyelocytic leukemia protein (PML) functions as a glucocorticoid receptor co-activator by sequestering Daxx to the PML oncogenic domains (PODs) to enhance its transactivation potential. | leukemia, |
| Promyelocytic leukemia protein (PML) functions as a glucocorticoid receptor co-activator by sequestering Daxx to the PML oncogenic domains (PODs) to enhance its transactivation potential. | leukemia, |
| PML/RARalpha plays a role for basal activity and retinoid-induced repression of the tissue factor promoter in acute promyelocytic leukemia cells. | leukemia, |
| Induction of promyelocytic leukemia (PML) oncogenic domains (PODs) by papillomavirus. | leukemia, |
| Concordant expression of proto-oncogene promyelocytic leukemia and major histocompatibility antigen HLA class I in human hepatocellular carcinoma. | leukemia,liver, |
| expression of proto-oncogene PML and HLA class I molecules were concordantly upregulated in hepatocellular carcinoma (HCC) and the expression of PML gene might be one of the mechanisms that leads to the increased expression of class I antigen in HCC | liver, |
| Kaposi s sarcoma-associated herpesvirus protein LANA2 disrupts PML oncogenic domains and inhibits PML-mediated transcriptional repression of the survivin gene. | sarcoma, |
| Design and synthesis of novel derivatives of all-trans retinoic acid demonstrate the combined importance of acid moiety and conjugated double bonds in its binding to PML-RAR-alpha oncogene in acute promyelocytic leukemia. | leukemia, |
| Covalent modification by SUMO is required for efficient disruption of PML oncogenic domains by Kaposi s sarcoma-associated herpesvirus latent protein LANA2. | sarcoma, |